The US Food and Drug Administration (FDA) has declined to approve Summit Therapeutics’ investigational cancer therapy ivonescimab for previously treated EGFR-mutated non-small cell lung cancer (NSCLC), citing insufficient evidence of an overall survival benefit.
The regulator issued a complete response letter for the drug’s biologics licence application on Sunday, concluding that the available clinical evidence did not establish a sufficiently favourable benefit-risk profile to support approval.
The decision follows results from the Phase III HARMONi trial, which evaluated ivonescimab in combination with chemotherapy against chemotherapy alone in patients with EGFR-mutated NSCLC whose disease had progressed following previous tyrosine kinase inhibitor (TKI) treatment.
Although the study showed a significant improvement in progression-free survival (PFS), reducing the risk of disease progression or death by 48% compared with chemotherapy alone, it did not achieve statistical significance for its overall survival endpoint.
Summit subsequently submitted updated survival data to the FDA, which the company said indicated a consistent improvement across Asian and Western patient subgroups.
But the regulator maintained that the PFS benefit, without a statistically significant OS improvement, was insufficient to demonstrate a positive benefit-risk profile.
Summit has said that it is disappointed by the decision but remains committed to advancing ivonescimab's clinical development across multiple cancer indications.
The setback comes as interest in bispecific immunotherapies continues to grow.
In September, AstraZeneca announced a $2bn investment in Summit, securing a ten per cent stake in the US biotech and establishing a collaboration to investigate combinations of ivonescimab with AstraZeneca's antibody-drug conjugate cancer therapies.
Attention is now turning to the Phase III HARMONi-3 trial, which is evaluating ivonescimab in combination with chemotherapy against Merck's pembrolizumab (Keytruda) plus chemotherapy in first-line NSCLC.
Initial overall survival and progression-free survival results in patients with squamous NSCLC could be available by the end of this year, with results from the non-squamous cohort expected in the first half of 2027.
The FDA rejection may also create an opportunity for competing developers of PD-(L)1/VEGF bispecific antibodies, including BioNTech and Bristol Myers Squibb, Pfizer and 3SBio, as well as AbbVie and RemeGen, to advance their respective clinical programmes.
A dual-targeting approach to cancer immunotherapy
Ivonescimab is an investigational bispecific antibody developed by China's Akeso that simultaneously targets two proteins involved in tumour development: programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF).
By inhibiting PD-1, the therapy aims to prevent cancer cells from evading immune detection, while blocking VEGF is intended to disrupt the formation of blood vessels that supply tumours with oxygen and nutrients.
The dual-targeting approach combines immune checkpoint inhibition with anti-angiogenic activity.
Summit Therapeutics acquired commercial rights to ivonescimab in the US, Canada, Europe and Japan from Akeso in 2022, in a licensing agreement valued at up to $5bn.
Akeso retained rights in China and other markets, where ivonescimab has secured approvals for three NSCLC indications.
The drug has attracted considerable industry interest following positive clinical findings in China, including a head-to-head study in which it outperformed Merck's Keytruda in progression-free survival among patients with PD-L1-positive NSCLC.
Despite the latest US regulatory setback, its wider clinical programme continues, with investigations spanning several solid tumours and combinations with other cancer therapies.